A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Eveline M. Dijkgraaf 1 , Saskia J.A.M. Santegoets 1 , An K.L. Reyners 2 , Renske Goedemans 1 , Hans W. Nijman 3 , Mariëtte I.E. van Poelgeest 4 , Arien R. van Erkel 5 , Vincent T.H.B.M. Smit 6 , Toos A.H.H. Daemen 7 , Jacobus J.M. van der Hoeven 1 , Cornelis J.M. Melief 8 , Marij J.P. Welters 1 , Judith R. Kroep 1, * , Sjoerd H. van der Burg 1, * 1 Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 2 Department of Clinical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands 3 Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands 4 Department of Gynecology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 5 Department of Radiology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 6 Department of Pathology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands 7 Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands 8 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands * These authors have contributed equally to this work Correspondence to: Sjoerd H. van der Burg, e-mail: shvdburg@lumc.nl Judith R. Kroep, e-mail: j.r.kroep@lumc.nl Keywords: ovarian cancer, p53, immunotherapy, chemoresistance, tumor immunity Received: May 27, 2015 Accepted: August 03, 2015 Published: August 14, 2015 ABSTRACT Purpose : Preclinical tumor models show that chemotherapy has immune modulatory properties which can be exploited in the context of immunotherapy. The purpose of this study was to determine the feasibility and immunogenicity of combinations of such an immunomodulatory chemotherapeutic agent with immunotherapy, p53 synthetic long peptide (SLP) vaccine and Pegintron (IFN-α) in patients with platinum-resistant p53-positive epithelial ovarian cancer (EOC). Experimental design : This is a phase 1/2 trial in which patients sequential 6 cycles of gemcitabine (1000 mg/kg 2 iv; n = 3), gemcitabine with Pegintron before and after the first gemcitabine cycle (Pegintron 1 μg/kg sc; n = 6), and gemcitabine and Pegintron combined with p53 SLP vaccine (0.3 mg/peptide, 9 peptides; n = 6). At baseline, 22 days after the 2 nd and 6 th cycle, blood was collected for immunomonitoring. Toxicity, CA-125, and radiologic response were evaluated after 3 and 6 cycles of chemotherapy. Results : None of the patients enrolled experienced dose-limiting toxicity. Predominant grade 3/4 toxicities were nausea/vomiting and dyspnea. Grade 1/2 toxicities consisted of fatigue (78%) and Pegintron-related flu-like symptoms (72%). Gemcitabine reduced myeloid-derived suppressor cells ( p = 0.0005) and increased immune-supportive M1 macrophages ( p = 0.04). Combination of gemcitabine and Pegintron stimulated higher frequencies of circulating proliferating CD4+ and CD8+ T-cells but not regulatory T-cells. All vaccinated patients showed strong vaccine-induced p53-specific T-cell responses. Conclusion : Combination of gemcitabine, the immune modulator Pegintron and therapeutic peptide vaccination is a viable approach in the development of combined chemo-immunotherapeutic regimens to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“Cancer immunotherapy has been shown to be an effective treatment modality in metastatic cancer, however, clinical efficacy is often delayed and only observed in a part of the treated cancer patients [3], including those with ovarian cancer [4, 5].”
BackgroundIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“Epithelial ovarian cancer (EOC) is likely to benefit from T-cell-based immunotherapy as it was observed that strong infiltration with CD8+ T-cells is correlated with enhanced survival and response to chemotherapy [6, 7].”
BackgroundInterferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617 · cited 1×
“144 cross-presentation of tumor antigens and to enhance survival of activated T cells, thereby enhancing the anti-tumor response [25-30].”
BackgroundHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · cited 1×
“Unfortunately, the EOC microenvironment is known to restrain the cytotoxic activity of effector lymphocytes in a direct fashion [8, 9] as well as indirectly by favoring the accumulation of regulatory T-cells (Tregs), myeloid-derived suppressor cells (MDSC) and M2 macrophages [10–12], associated with suppression of tum…”
BackgroundSuzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185
Self-citationShevchenko, I., Karakhanova, S., Soltek, S., Link, J., Bayry, J., Werner, J., Umansky, V., & Bazhin, A. V. (2013) · International Journal of Cancer · doi:10.1002/ijc.27990 · Cited by 168
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Cited by
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationPolymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Self-citation
Metadata
- Authors
- Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T. A. H. H., van der Hoeven, J. J. M., Melief, C. J. M., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-08-14
- Volume
- 6
- Issue
- 31
- Pages
- 32228-32243
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1960571207
- Cited by
- 83
- References
- 8
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. https://app.cochat.ai/papers/10.18632/oncotarget.4772
- The paper
- Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T. A. H. H., van der Hoeven, J. J. M., Melief, C. J. M., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2015). A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. https://doi.org/10.18632/oncotarget.4772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.